References
1. Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor. Surgical oncology 2008;17:129-138.
2. Hopkins T, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). European Journal of Surgical Oncology (EJSO) 2008;34:844-850.
3. Stamatakos M, Douzinas E, Stefanaki C, et al. Gastrointestinal stromal tumor. World journal of surgical oncology 2009;7:61.
4. Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer epidemiology 2016;40:39-46.
5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human pathology 2002;33:459-465.
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
7. Loong HH. Gastro-intestinal stromal tumours: a review of current management options. HONG KONG MEDICAL JOURNAL 2007;13:61.
8. Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13:265-74.
9. Samelis G, Ekmektzoglou K, Zografos G. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy. European Journal of Surgical Oncology (EJSO) 2007;33:942-950.
10. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of surgery 2000;231:51.
11. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Annals of Surgical Oncology 2002;9:831-839.
12. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 2002;347:472-480.
13. Jones RL. Practical aspects of risk assessment in gastrointestinal stromal tumors. Journal of gastrointestinal cancer 2014;45:262-267.
14. Bülbül DG. Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology 2012;23:203-211.
15. Seker M, Sevinc A, Yildiz R, et al. Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey. Hepato-gastroenterology 2013;60:768-775.
16. Selcukbiricik F, Yalçın S, Tural D, et al. Gastrointestinal stromal tumors in Turkey: experiences from 3 centers. Oncology Research and Treatment 2013;36:18-24.
17. Choi AH, Hamner JB, Merchant SJ, et al. Underreporting of Gastrointestinal Stromal Tumors: Is the True Incidence Being Captured? J Gastrointest Surg 2015;19:1699-703.
18. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. The American journal of surgical pathology 2006;30:477-489.
19. Lv M, Wu C, Zheng Y, et al. Incidence and survival analysis of gastrointestinal stromal tumors in shanghai: a population-based study from 2001 to 2010. Gastroenterol Res Pract 2014;2014:834136.
20. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC cancer 2007;7:230.
21. Rubio J, Marcos-Gragera R, Ortiz M, et al. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. European journal of cancer 2007;43:144-148.
22. Bertin M, Angriman I, Scarpa M, et al. Prognosis of gastrointestinal stromal tumors. Hepato-gastroenterology 2006;54:124-128.
23. Tryggvason G, Kristmundsson Þ, Örvar K, et al. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990–2003. Digestive diseases and sciences 2007;52:2249-2253.
24. Chiang N-J, Chen L-T, Tsai C-R, et al. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998–2008: a nation-wide cancer registry-based study. BMC cancer 2014;14:102.
25. Özgüç H, Yilmazlar T, Yerci Ö, et al. Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. Journal of Gastrointestinal surgery 2005;9:418-429.
26. Rubió-Casadevall J, Borràs JL, Carmona-García MC, et al. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World journal of surgical oncology 2015;13:47.
27. Call J, Walentas CD, Eickhoff JC, et al. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC cancer 2012;12:90.
28. Rudolph P, Chiaravalli A, Pauser U, et al. Gastrointestinal mesenchymal tumors-immunophenotypic classification and survival analysis. Virchows Archiv 2002;441:238-248.
29. Nagasako Y, Misawa K, Kohashi S, et al. Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor. Gastric Cancer 2003;6:168-172.
30. Del Rio P, Bertocchi E, Dell'Abate P, et al. Gastrointestinal Stromal Tumors: a single Center retrospective 15 years study. Ann Ital Chir 2016;87:426-432.
31. Manrique MN, Soriano C, Yábar A, et al. [Gastrointestinal stromal tumors: clinicopathologic and survival evaluation in Rebagliati Hospital]. Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 2012;32:357-365.
32. Demetri GD, Von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network 2010;8:S-1-S-41.
33. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites, In Seminars in diagnostic pathology, Elsevier, 2006.
34. Feng F, Tian Y, Liu Z, et al. Clinicopathological features and prognosis of colonic gastrointestinal stromal tumors: evaluation of a pooled case series. Oncotarget 2016;7:40735.
35. Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The lancet oncology 2009;10:1045-1052.
36. Alvarado-Cabrero I, Vázquez G, Sierra Santiesteban FI, et al. Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico. Annals of Diagnostic Pathology 2007;11:39-45.
37. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Modern Pathology 2000;13:1134-1142.
38. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. The American journal of surgical pathology 2005;29:52-68.
39. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives of pathology & laboratory medicine 2006;130:1466-1478.
40. Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995;19:207-16.
41. Plank L, Buzalkova V, Szepe P, et al. Gastrointestinal stromal tumor after tyrosine kinase inhibition therapy: a review of biopsies of 34 patients with clinically suspected relapse and/or progression of the tumor. Neoplasma 2017;64:464-473.
42. Wang X, Mori I, Tang W, et al. Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Japanese journal of clinical oncology 2002;32:347-351.
43. Pyo J-S, Kang G, Sohn JH. Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis. Int J Biol Markers 2016;31:0-0.
44. Ozer-Stillman I, Strand L, Chang J, et al. Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor. Clin Cancer Res 2015;21:295-302.